Article info
PDFResearch Article
Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
- ↵a Asim.Amin{at}carolinashealthcare.org
- ↵b adudek{at}uic.edu
- ↵c tlogan{at}iu.edu
- ↵d rlance{at}urologyofva.net
- ↵e jholzbeierlein{at}kumc.edu
- ↵f Jennifer.Knox{at}uhn.ca
- ↵g vmaster{at}emory.edu
- ↵h SPal{at}coh.org
- ↵i wmiller{at}ldi.jgh.mcgill.ca
- ↵j lkarsh{at}tucc.com
- ↵k itcherepanova{at}argostherapeutics.com
- ↵l mdebenedette{at}argostherapeutics.com
- ↵m lwilliams{at}argostherapeutics.com
- ↵n dplessinger{at}argostherapeutics.com
- ↵o cnicolette{at}argostherapeutics.com
- ↵p robert.figlin{at}cshs.org
Citation
Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
Publication history
- Received October 6, 2014
- Accepted March 2, 2015
- First published April 21, 2015.
Online issue publication
April 21, 2015
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© The Author(s). 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.